Press release
September 16, 2026
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
Braveheart Bio, Inc. (BRVE)
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the